AI assistant
Dechra Pharmaceuticals PLC — Share Issue/Capital Change 2019
Mar 15, 2019
4797_rns_2019-03-15_b19f542b-2244-4a6f-83d8-46493646cc0d.html
Share Issue/Capital Change
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 9211S
Dechra Pharmaceuticals PLC
15 March 2019
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to a ris.
Date: 15 March 2019
| Name of applicant: | Dechra Pharmaceuticals PLC | |||
| Name of scheme: | Long-Term Incentive Scheme | |||
| Period of return: | From: | 15 September 2018 | To: | 14 March 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 156,249 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 6,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 155,834 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 6,415 | |||
| Name of contact: | Melanie Hall |
| Telephone number of contact: | 01606 814 730 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to a ris.
Date: 15 March 2019
| Name of applicant: | Dechra Pharmaceuticals PLC | |||
| Name of scheme: | Approved Share Option Scheme | |||
| Period of return: | From: | 15 September 2018 | To: | 14 March 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 19,469 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 5,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 11,633 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 12,836 | |||
| Name of contact: | Melanie Hall |
| Telephone number of contact: | 01606 814 730 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to a ris.
Date: 15 March 2019
| Name of applicant: | Dechra Pharmaceuticals PLC | |||
| Name of scheme: | Unapproved Share Option Scheme | |||
| Period of return: | From: | 15 September 2018 | To: | 14 March 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 90,440 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 40,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 16,202 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 114,238 | |||
| Name of contact: | Melanie Hall |
| Telephone number of contact: | 01606 814 730 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to a ris.
Date: 15 March 2019
| Name of applicant: | Dechra Pharmaceuticals PLC | |||
| Name of scheme: | SAYE Scheme | |||
| Period of return: | From: | 15 September 2018 | To: | 14 March 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 13,654 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 105,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 62,533 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 56,121 | |||
| Name of contact: | Melanie Hall |
| Telephone number of contact: | 01606 814 730 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
BLREADDLFDDNEFF